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08174635Purpose: Hypothyroidism (HT) is a frequent late side effect of Hodgkin’s lymphoma (HL) therapy. The purpose of
this study is to determine dose–volume constraints that correlate with functional impairment of the thyroid gland
in HL patients treated with three-dimensional radiotherapy.
Methods andMaterials: A total of 61 consecutive patients undergoing antiblastic chemotherapy and involved field
radiation treatment (median dose, 32 Gy; range, 30–36 Gy) for HL were retrospectively considered. Their median
age was 28 years (range, 14–70 years). Blood levels of thyroid-stimulating hormone (TSH), free triiodo-thyronine
(FT3), free thyroxine (FT4), and thyroglobulin antibody (ATG) were recorded basally and at different times after
the end of therapy. For the thyroid gland, normal tissue complication probability (NTCP), dosimetric parameters,
and the percentage of thyroid volume exceeding 10, 20, and 30 Gy (V10, V20, and V30) were calculated in all pa-
tients. To evaluate clinical and dosimetric factors possibly associated with HT, univariate and multivariate logistic
regression analyses were performed.
Results: Eight of 61 (13.1%) patients hadHTbefore treatment andwere excluded from further evaluation. At ame-
dian follow-up of 32 months (range, 6–99 months), 41.5% (22/53) of patients developed HT after treatment. Uni-
variate analyses showed that all dosimetric factors were associated with HT (p < 0.05). On multivariate analysis,
the thyroid V30 value was the single independent predictor associated with HT (p = 0.001). This parameter divided
the patients into low- vs. high-risk groups: if V30 was # 62.5%, the risk of developing HTwas 11.5%, and if V30
was >62.5%, the risk was 70.8% (p < 0.0001). ACox regression curve stratified by two levels of V30 value was cre-
ated (odds ratio, 12.6).
Conclusions: The thyroid V30 predicts the risk of developing HTafter sequential chemo-radiotherapy and defines
a useful constraint to consider for more accurate HL treatment planning.  2012 Elsevier Inc.
Hodgkin’s lymphoma, Radiotherapy, Hypothyroidism, Dosimetric constraints, Thyroid gland.INTRODUCTION
Hypofunction of the thyroid gland is one of themost common
and long-known late side effects described in literature after
therapeutic irradiation of the cervical region for neoplasms
such as head-and-neck squamous cell carcinoma (1–6) and
lymphomas (7–12). Radiation-induced hypothyroidism
(HT) may be either subclinical, as manifested by increased
serum thyrotropin and normal serum-free thyroxine concen-
trations, or clinically overt, with laboratory findings showing
increased serum thyrotropin and low free serum thyroxine
concentrations, eventually coupled with signs such as slow
reflexes, bradycardy, hypotension, cold intolerance, fatigue,t requests to: Roberto Pacelli, M.D., Dipartimento di
ca per Immagini e Radioterapia, Universita ‘‘Federico
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1802and unexplainedweight gain (13).HT typically occurswithin
5 years after completing radiation treatment, with a peak of
occurrences at 2 to 3 years (2, 9), but it has been reported
even 20 to 25 years after radiotherapy (7, 14).
In Hodgkin’s lymphoma (HL) patients, the irradiation of
the thyroid region has been documented to induce approxi-
mately up to a 50% risk of developing HT and a 20% risk
of developing thyroid nodules (11, 12, 15, 16). Among the
most important factors associated with the incidence of
HT is the total radiation dose, whereas the role of
chemotherapy on radiation-induced thyroid dysfunction is
not clear and is still debated (2, 14).Conflict of interest: none.
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the risk of HT, either clinically overt or subclinical, was
found to be 51% for patients receiving doses of 35 to 45
Gy (15) and 40% for patients receiving doses of 30 to 36
Gy (14) compared with 12% to 27% for patients receiving
doses of 15 to 30 Gy (14, 15, 17, 18). Despite this clear-
cut dose–effect relationship, a review of published studies
shows that a dose–volume histogram metric for the predic-
tion of the risk of thyroid radiation-induced abnormalities
has not yet been determined. The current trend in radiation
oncology is to pay more attention in determining acceptable
dose–volume constraints for critical organs so as to limit
normal tissue risks (19). Recently, the Quantitative Analysis
of Normal Tissue Effects in the Clinic (QUANTEC) reviews
have given information on dose, volume, and outcome for
many different organs but not for the thyroid gland (20). In-
deed, to date and to our best knowledge, only a few investi-
gators have performed clinical dose–volume histogram
analysis for thyroid disorders after radiotherapy (5, 21,
22). The limitations of these studies are the lack, for most
patients, of the baseline hormone values assessed before
radiation therapy and the failure to identify a dose–volume
threshold value. All of these studies concerned head-and-
neck cancer patients treated with doses on the order of 70
Gy, which are much higher than those used in radiotherapy
for HL. Noteworthy is the suggestion by Agkun et al. (21)
and Yoden et al. (22) that doses to the neck exceeding 30
Gy have a significant impact on the TSH peak.
In recent years, for HL radiotherapy, several delivery tech-
niques such as intensity-modulated radiation therapy tech-
niques, with or without inverse planning optimization, and
even three-dimensional proton radiotherapy have been pro-
posed (23–29). These advanced tools increase treatment
accuracy avoiding normal organs (i.e., the heart, lungs, and
thyroid) and thus improve long-term effects and quality of
life of survivors. Using more sophisticated techniques is of
great importance for HL patients in whom low mean age
and high rate of cure make them particularly at risk for de-
veloping late side effects and secondary neoplasms. In this
framework, the definition of dosimetric constraints and pre-
dictive factors becomes more clinically relevant so as to plan
optimal strategies and to reduce the risk of late radiation ef-
fects; thus specific studies on dose–effect relationships for
radiation-induced thyroid toxicity are needed.
With the aim to determine thyroid dose–volume con-
straints that correlate with HT, in the present study we
have performed a retrospective analysis of 61 patients
treated for HL with chemo- and radiation therapy for
whom thyroid hormone levels, clinical data, and thyroid
dose distribution were available.METHODS AND METERIALS
Patient selection
In this study, we reviewed data on 61 consecutive patients with
Hodgkin’s disease and for whom pretreatment thyroid function
tests were available. All patients received postchemotherapy supra-diaphragmatic involved-field radiation therapy at the Department
of Radiotherapy of the University ‘‘Federico II’’ of Naples between
November 2001 and April 2009. The patients’ median age was 28
years (range, 14 to 70 years).
Chemotherapy consisted of four to six cycles either of ABVD
(doxorubicin 25 mg/m2, bleomycin 10 mg/m2, vinblastine 6 mg/
m2, and dacarbazine 375 mg/m2, all drugs i.v. and administered
Days 1 and 15, every 28 days) or VEBEP (vinblastine 6 mg/m2
i.v., Days 1 and 15; etoposide 80 mg/m2 i.v., Days 1–3 and Days
15–17; bleomycin 10 mg/m2 i.v., Days 1 and 15; epidoxorubicin
40 mg/m2 i.v., Days 1 and 15; and prednisone 40 mg/m2 p.o.,
Days 1–5 and 15–19).
Radiotherapy and dosimetric analysis
All patients were treated with full three-dimensional radiation
treatment planning and data for dosimetric analysis were retrospec-
tively obtainable for 56 of 61 patients.
Treatment planning was based on CT performed with the patient
in supine position using vacuum-locked mattress with the patient’s
arms above the head. Scans were acquired using 5-mm slices of
a multislices scanner. CT images were electronically transferred
to the Focal Ease 4.2 CT Simulation software (Computerized Med-
ical System, St Louis, MO) for target and critical organs contour-
ing. Clinical target volume (CTV) included the nodal sites
involved at the time of diagnosis (29); planning target volume
(PTV) included CTV plus a 1-cm margin. For all patients, the thy-
roid gland was deliberately delineated by the same radiation oncol-
ogist.
All patients underwent three-dimensional treatment planning us-
ing XiO computer software (version 4.4, Computerized Medical
System, St. Louis, MO). The dose distribution was calculated using
an appropriate algorithm in the presence of heterogeneous tissues.
Radiotherapy was administered using 6- to 20-MV photon beams
from a linear accelerator with AP and PA fields shaped to the pro-
jection of the PTV in the beam’s-eye view. The prescription dose
was specified at the centre of PTV. Field weightings were adjusted
to achieve the maximum possible uniform distribution in the target
volume (95% of prescription dose delivered at least to 95% of the
PTV). A total median dose of 32 Gy (range, 30–36 Gy) in 20 daily
fractions of 1.5 to 1.6 Gy was planned. The AP-PA fields included
the entire thyroid gland, a part of it or did not include the thyroid at
all, depending on the target to be irradiated.
For the thyroid gland, the absolute volume, the dose–volume his-
togram (DVH), the minimum, maximum, and mean doses (TDmin,
TDmax, and TDmean), the percentage of thyroid volume exceeding
10, 20, and 30 Gy (V10, V20, and V30 respectively) were calcu-
lated. Furthermore, we assessed the normal tissue complication
probabilities (NTCP) for the thyroid. We used a NTCP tool in
XiO based on Lyman–Kutcher–Burman (LKB) model (30–32).
The parameters for NTCP calculations were volume effect =
0.22, slope = 0.26, and tolerance dose TD5/5 = 45 Gy.
Thyroid function follow-up evaluation
Initial and follow-up evaluation consisted of history and physical
examination and thyroid hormones serum determination that were
recorded before chemotherapy and periodically after the end of the
radiation treatment. No patient had comorbid conditions such as di-
abetes and collagen vascular disease. Thyroid stimulating hormone
(TSH), free triiodo-thyronine (FT3), free thyroxine (FT4), and thy-
roglobulin antibody (TGA) blood levels were evaluated.
The time of onset of HTwas defined as the interval between the
end of radiotherapy and the first altered thyroid hormone laboratory
Table 1. Patient, disease, and treatment characteristics
Characteristic n %
Age (y)
14–25 23 43.4
26–35 13 24.5
1804 I. J. Radiation Oncology d Biology d Physics Volume 82, Number 5, 2012value. It must be remarked that we consider an out-of-range value
as an alteration when confirmed by a subsequent laboratory test.
A diagnosis of HTwas based on TSH value grater than the max-
imum value of laboratory range and/or FT3 and/or FT4 values
lower than the minimum value of laboratory range, regardless of
whether any symptom was present.36–45 9 17
46–70 8 15.1
Sex
Male 25 47.2
Female 28 52.8
Histology
Nodular sclerosis 38 71.7
Mixed cellularity 10 18.9
Lymphocyte-rich-classical 5 9.4
Stage
I–II 42 79.2
III–IV 11 20.8
Radiotherapy dose delivered
30 Gy 23 43.4
32 Gy 25 47.2
36 Gy 5 9.4
Chemotherapy regimen
ABVD 15 28.3
VEBEP 38 71.7
Abbreviations: ABVD = doxorubicin, bleomycin, vinblastine,
and dacarbazine; VEBEP = vinblastine, etoposide, bleomycin, epi-Statistical analysis
Univariate analysis was used to evaluate correlations between
clinical factors (sex, age, disease stage, and thyroid gland volume),
dosimetric factors (total prescribed dose and dosimetric parameters
from the thyroid DVH), and the incidence of HTafter radiotherapy.
Dichotomic variables were tested by Pearson Chi-square test. The
median and the interquartile range were used to describe all contin-
uous variables and nonparametric techniques were used for analyz-
ing them (Mann–Whitney U test). For multivariate analysis on
significant dosimetric parameters the Cox regression was adopted.
A receiver operating characteristic (ROC) curve analysis was per-
formed to find possible threshold values for dividing patients in
high-risk and low-risk groups regarding dosimetric parameters. Cu-
mulative incidence of HTwas calculated using Kaplan–Meier sur-
vival analyses. All statistical tests were two-sided, and a p value of
0.05 was considered statistically significant. Statistical analysis
was performed with SPSS 15.0 statistical software (SPSS Inc.,
Chicago, IL).Fig. 1. Kaplan–Meier estimated cumulative incidence curve of hy-
pothyroidism (HT) at 5 years.
doxorubicin, and prednisone.RESULTS
Thyroid hormone levels were basally evaluated on 61 pa-
tients. Eight patients (13.1%) had HT before treatment, and
were consequently excluded from further evaluation. Demo-
graphic, disease, and treatment characteristics of the remain-
ing 53 patients are shown in Table 1.
Of 53 patients, 22 (41.5%) developed laboratory evidence
of HT at a median follow-up of 32 months (range, 6–99
months) after the end of radiation treatment. The Kaplan–
Meier estimated incidence curve of HT at 5 years is shown
in Fig. 1. Estimated incidences of HT at 24 months and at
60 months after treatment were 43.5% and 49.1%, respec-
tively.
The no-HT group and the HT group of patients were ana-
lyzed with respect to different clinical parameters. Univari-
ate analysis was performed, and there was no significant
difference in the distribution of clinical parameters between
the HT and no-HT groups (Table 2).
For 50 of the 53 patients considered so far 3D treatment
planning data were available. The following statistical anal-
yses were performed on this subset of patients. Univariate
analysis was used on total prescribed dose and on thyroid
dosimetric parameters to study their impact on the develop-
ment of HT. Results are shown in Table 3. All dosimetric
parameters resulted significantly associated with HT, but
they are not independent of each other, as shown by the mul-
tivariate analysis (Table 4). The V30 is the only variable that
independently contributes to the prediction of HT (p =
0.001). Figure 2 shows the V30 value distribution between
HT and no-HT groups. From ROC analyses (Fig. 3), a V30
of 62.5% resulted as threshold value. Our analysis shows
that V30 separates patients into low- and high-risk groups;the incidence of radiation-induced HT in the group with
V30 # 62.5% and V30 > 62.5 was 11.5% and 70.8% re-
spectively (p < 0.0001). A Cox regression curve stratified
by two levels of V30 value (odds ratio, 12,6) is shown in
Fig. 4a.
Table 4. Multivariate analysis of factors related to
development of HT after radiotherapy
Factor p value
V30 (%) 0.001
Dmin (Gy) 0.419
Dmax (Gy) 0.705
Dmean (Gy) 0.759
DTot (Gy) 0.455
NTCP 0.878
V10 (%) 0.776
V20 (%) 0.808
Abbreviations as in Table 3.
Table 2. Clinical factors in patients without hypothyroidism
(no-HT) and with hypothydroidism (HT)
No-HT group HT group p value
Age (y) 29 (21.0–46.0) 27.5 (21.0–35.3) 0.38*
Thyroid volume (cc) 13.8 (11.6–19.7) 14.5 (9.7–17.3) 0.43*
Follow-up (mo) 30.5 (8–99) 40.0 (6–96) 0.28*
Sex
Female 46.4% 53.6% 0.059y
Male 72.0% 28%
Stage
I–II 51.2% 48.8% 0.16y
III–IV 80.0% 20.0%
Median value and interquartile range are indicated. For dichoto-
mous variables, percentages are indicated.
* Mann–Whitney U test.
y Chi-square test.
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Hodgkin’s lymphoma, characterized by a rate of nearly
90% of long surviving patients and by a low average age at
diagnosis, is a highly curable disease thanks to antiblastic
chemotherapy and radiation therapy. However, these treat-
ment modalities imply the risk of long-term side effects in-
cluding HT. It has been previously shown that HT can be
caused by radiotherapy on the neck region and that doses
even <40 Gymay induce HT in a relevant fraction of patients
(14, 18). To treat supradiaphragmatic HL, the planning target
volume must frequently include the whole thyroid gland or
a large part of it. On the other hand, recent improvements
in HL radiotherapy techniques recall attention on dose–
volume histogram metrics for the prediction of the risk of
HT. Normal tissue late effects of ionizing radiation are an
important part of plan evaluation in radiation oncology.
The technological advances in radiation therapy techniques
make, today more than ever before, a thorough knowledge
of the relation of dose, volume, and outcome for the
normal tissues in the irradiated field mandatory. Reliable
3D quantitative data on which clinical decisions can be
made are already available for many organs (19, 20), but
still no data exist for the thyroid.Table 3. Total prescribed dose and dosimetric parameters
from thyroid DVH in no-HT and HT groups
No-HT group HT group p value*
DTot (Gy) 30.0 (30.0–32.0) 32.0 (32.0–32.0) 0.002
Dmin (Gy) 1.7 (0.8–25.2) 28.8 (17.2–30.3) 0.0004
Dmax (Gy) 31.2 (30.3–33.0) 32.5 (32.0–33.5) 0.041
Dmean (Gy) 18.9 (15.8–29.8) 31.5 (30.4–32.6) 0.0004
NTCP 6.4 (4.1–9.8) 12.4 (10.4–14.7) 0.001
V10 (%) 59.5 (48.4–59.5) 100.0 (100.0–100.0) 0.002
V20 (%) 53.7 (44.8–100.0) 100.0 (100.0–100.0) 0.003
V30 (%) 34.7 (5.0–100.0) 98.1 (80.7–100.0) 0.0002
Abbreviations: Dmax = maximum thyroid dose; Dmean = mean
thyroid dose; Dmin = minimum thyroid dose; DTot = total prescribed
dose; HT = hypothyroidism; NTCP = normal tissue complication
probability; VX = percentage of thyroid volume exceeding X Gy.
Median value and interquartile range are indicated.
* Mann–Whitney U test.In this study, to derive quantitative information about HT
risk for a given treatment plan, we have retrospectively eval-
uated the outcome of 61 HL patients for whom the thyroid
functional status before the treatment was known. We were
essentially interested in determining a dose–volume thresh-
old value that could separate patients at HT high risk from
those at HT low risk. The final aim was to single out a con-
straint for plan optimization, for clinical decisions, and for
patients risk information.
In our cohort of patients, at a median follow up of 32
months, we found an incidence of HT of 41.5% that is in
a good agreement with the incidence of HT reported in the
literature by Kuten et al. (14) Indeed, the authors reported
a 40% incidence of HT after 30 to 36 Gy in HL patients
treated with chemotherapy followed by radiotherapy. It
must be pointed out that the major limitation of our study
could be the lack for some patients (22%) of long-term
(>24 months) clinical follow-up. In any case, when correct-
ing for the length of follow-up, no differences in our analysis
were found.
To identify a clinically relevant and accessible factor upon
which to classify HL patients at risk for HT, we first analyzed
different patient-related factors. Our results showed that age,
thyroid volume, and stage were not associated with HT. In
particular, it is worth noting that the overall thyroid volume
was not correlated with radiation-induced HT. In accordance
with the literature (5), a trend was found (p = 0.059), sug-
gesting that female gender was associated with a higher
risk of thyroid toxicity. In any case, it must be considered HT group  no-HT group
0
50
100
p= 0.0002
)
%
(
0
3
V
Fig. 2. Thyroid V30 values in the hypothyroidism (HT) group and
no-HT group. Lines represent median values for the two groups.
Fig. 3. Receiver operating characteristic (ROC) curve for thyroid
V30 threshold definition.
Fig. 4. Cumulative incidence of hypothyroidism stratified by two
levels of V30 (a) and by two levels of V20 (b).
1806 I. J. Radiation Oncology d Biology d Physics Volume 82, Number 5, 2012that the estimated rate of HT in the general population is
higher in women than in men (33, 34).
The homogeneity of clinical data and therapy, CT-based
planning with 1 physician contouring thyroid gland for all
patients in the study allowed us to focus on radiation dosi-
metric factors. Considering dose–volume parameters, the
V30 emerged as the only independent predictor of HT. In
our results, V30 was shown to be an effective stratification
criterion dividing patients into high-risk and low-risk groups
with an odds ratio of 12.6 (Fig. 4a). By ROC analysis we
identified a threshold value for thyroid V30 of 62.5% that
can be used as constraint in HL treatment planning. It is in-
teresting to note that a dose of 30 Gy was previously indi-
cated to significantly affect the thyroid function (21, 22).
Considering this finding together with the data on
development of HT after hemithyroidectomy, and our
results on V30, it is possible to speculate that the dose of
30 Gy represents a critical dose for thyrocyte activity.
Indeed, if this dose is given to a volume equal or less than
half of thyroid gland, we found a risk of HT of 11.5%
comparable with that of hemithyroidectomy reported to be
10.9% (35).
Furthermore, the data coming from univariate analysis
suggest that even if V20 and V10 resulted not significant
on the multivariate analysis, they may play a role as a con-
straint in the treatment plans in which the prescription
dose is lower than 30 Gy. Repeating the same procedure per-
formed for V30, we found a threshold value for V20 equal to
82.4%. In this case, the incidence of radiation-induced HT in
the group with V20 # 82.4% and V20 > 82.4% was 13.6%
and 60.7% respectively (p = 0.001). A Cox regression curve
stratified by two levels of V20 value (odds ratio, 9.4) is
shown in Fig. 4b. This last result must be considered in
view of the data coming from the German Hodgkin Study
Group HD10 that, for patients with early stage and favorable
histology, defines a new standard of care with two cycles of
ABVD and 20 Gy involved-field radiotherapy (36). It should
be noted that a threshold value of 82.4% for V20 is quitea high percentage of thyroid volume and as a consequence
not difficult to achieve during the treatment planning phases.
We have recently shown (29) that, using a forward
planned IMRT instead of the conventional technique for
treating Hodgkin’s lymphoma, the thyroid V30 value can
be easily reduced, on average, from 80% to 20%, which is
much below the threshold value proposed here. Accordingly,
in our clinical practice, we adopted forward planned IMRT
as a standard technique, and we included thyroid V30 as
Radiation-induced hypothyroidism in Hodgkin’s lymphoma d L. CELLA et al. 1807a treatment constraint; in particular, we defined a threshold
value for V30 of 62.5%. We expect in this way to greatly re-
duce the incidence of radiation-induced HT in our patients in
the future.
CONCLUSION
In conclusion, we identified the thyroidV30 value as a pre-
dictor of the risk of developing HT in HL patients treatedwith sequential chemo-radiotherapy. We have also showed
that a V30 of 62.5% is a dose–volume threshold value that
can be easily included in the optimization process of treat-
ment planning for supradiaphragmatic HL so as to consider-
ably reduce the risk of developing radiation-induced HT.
Additional threshold values have been identified, such as
V20, that could be used if a new standard of care with lower
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